Search

anti vegf header

Editorial Feature:

Anti-VEGF: The Next Generation

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Show Description +

When a new wet AMD case presents with a large PED and persistent SRF, how do you decide if—and when—to switch agents? Host David Miller, MD, welcomes Esther Kim, MD, and Ehsan Rahimy, MD, to explore navigating PEDs, timing a switch to next-gen anti-VEGF agent, and setting revisit cadence.

Posted: 11/10/2025

Keywords:

aflibercept

•

faricimab

•

Neovascular Age-Related Macular Degeneration

•

Pigment epithelial detachment, PED

•

switching

•

regeneron

•

Eylea

•

eylea hd

•

vabysmo

Up Next

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

St<strike>ep</strike>upid Edits in a Neovascular AMD Patient

Stepupid Edits in a Neovascular AMD Patient

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Back to All Videos

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

When a new wet AMD case presents with a large PED and persistent SRF, how do you decide if—and when—to switch agents? Host David Miller, MD, welcomes Esther Kim, MD, and Ehsan Rahimy, MD, to explore navigating PEDs, timing a switch to next-gen anti-VEGF agent, and setting revisit cadence.

Posted: 11/10/2025

Keywords:

aflibercept

•

faricimab

•

Neovascular Age-Related Macular Degeneration

•

Pigment epithelial detachment, PED

•

switching

•

regeneron

•

Eylea

•

eylea hd

•

vabysmo

Please log in to leave a comment.